22-MULTI-52-EP-PMC: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies

Grants and Contracts Details

StatusActive
Effective start/end date11/11/228/29/24

Funding

  • Ellipses Pharma Limited: $48,289.00